Why Curaleaf Stock Is Skyrocketing Right Now – The Untold Momentum

Curaleaf just flipped the script. Again.

While legacy markets yawn, this cannabis heavyweight is printing gains like a meme coin on stimulants—no hype, just relentless execution. Here’s the breakdown.

The Catalysts No One Saw Coming

Federal reform whispers? Check. Monster earnings beat? Obviously. Retail traders finally waking up to the sector? Oh, you bet.

Short Sellers Getting Torched

Bears thought they had this one pinned. Now they’re covering at 52-week highs—classic Wall Street genius.

Bottom line: When a stock moves like this in a sideways market, either the CEO’s hiding an alien tech partnership… or the smart money’s front-running policy changes. Place your bets.

How good were those Q2 results?

But Curaleaf's Q2 update didn't seem all that great -- at least, not at first glance.

The company's net revenue tumbled 8% year over year to $314.5 billion. Its net loss from continuing operations worsened, from $48.6 million in the second quarter of 2024 to $50.6 million in the recent quarter. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) also fell by 9.7% year over year to $65.5 million.

But investors seem to be focusing on what appears to be stabilization in the U.S. cannabis market (domestic revenue increased from the first quarter of 2025) combined with Curaleaf's strong momentum in international markets. The company's international sales could grow even more thanks to its recently receiving a license to operate in Turkey.

Image source: Getty Images.

Is Curaleaf stock a buy?

I'm not convinced that Curaleaf stock is a great pick for most investors, though. The company remains unprofitable. It still faces headwinds in the U.S. market, which represents roughly 87% of total revenue. Perhaps Curaleaf's Q2 update momentum will continue, but I won't be surprised if the sizzle for this cannabis stock soon fizzles out.